Criteria of sensitivity to azoles;Criterios de sensibilidad a los azoles

Revista Espanola de Quimioterapia

Volumn 17, Issue 1, 2004, Pages 83-90

  Gil Tomas J ^a   Rubio Calvo, C ^a   Benito Ruesca, R ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE;

AGAR GEL DIFFUSION; ANTIBIOTIC SENSITIVITY; COLORIMETRY; CONFERENCE PAPER; DRUG INDICATION; IN VITRO STUDY; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; SPAIN;

ANTIFUNGAL AGENTS; AZOLES; FUNGI; MICROBIAL SENSITIVITY TESTS;

EID: 2542492137     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Swartz, M.N. Impact of antimicrobial agents and chemotherapy from 1972 to 1998. Antimicrob Agents Chemother 2000; 44: 2009-2016.
2. Calhoun, D.L., Roberts, G.D., Galgiani, J.N. y cols. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol 1986; 23: 298-301.
3. Galgiani, J.N., Reiser, J., Brass, C., Espinel-Ingroff, A., Gordon, M.A., Kerkering, T.M. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother 1987; 31: 1343-1347.
4. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard NCCLS document M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa 1992.
5. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard NCCLS document M27-T. National Committee for Clinical Laboratory Standards, Wayne, Pa 1995.
6. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa 1997.
7. Rex, J.H., Nelson, P.W., Paetznick, V.L., Lozano-Chiu, M., Espinel-Ingroff, A., Anaissie, E.J. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998; 42: 129-134.
8. Marr, K.A., Rustad, T.R., Rex, J.H., White, T.C. The trailing endpoint phenotype in antifungal susceptibility testing is pH-dependent. Antimicrob Agents Chemother 1999; 43: 1383-1386.
9. Odds, F.C., Vranckx, L., Woestenborghs, F. Antifungal susceptibility testing of yeasts: Evaluation of technical variables for test automation Antimicrob Agents Chemother 1995; 39: 2051-2060.
10. Pfaller, M.A., Messer, S.A., Coffman, S. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870. J Clin Microbiol 1995; 33: 1094-1097.
11. Rodríguez-Tudela, J.L., Berenguer, J., Martínez-Suá rez, J.V., Sánchez, R. Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. Antimicrob Agents Chemother 1996; 40: 1998-2003.
12. Cuenca-Estrella, M., Díaz-Guerra, T.M., Mellado, E., Rodríguez-Tudela, J.L. Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol 2001; 39: 525-532.
13. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts, 2nd ed. Approved Standard NCCLS document M27-A2, Wayne, Pa 2002.
14. Revankar, S.G., Kirkpatrick, W.R., McAtee, R.K. y cols. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol 1998; 36: 153-156.
15. Arthington-Staggs, B.A., Warnock, D.W., Morrison, C.J . Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother 2000; 44: 2081-2085.
16. Subcommittee of Antifungal Susceptibility Testing of the European Committee on Antibiotic Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. EUCAST Discussion document E, Dis 7.1 ESCMID, Taufkirchen 2002.
17. Cuenca-Estrella, M., Moore, C.B., Barchiesi, F. y cols. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2003; 9: 467-474.
18. Cuenca-Estrella, M., Lee-Yang, W., Ciblak, M.A. y cols. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother 2002; 46: 3644-3647.
19. Arthington-Staggs, B.A., Lee-Yang, W., Ciblak, M.A. y cols. Comparison of visual and spectrophotometric methods of broth microdilution MIC endpoint determination and evolution of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 2002; 46: 2477-2481.
20. Espinel-Ingroff, A., Dawson, K., Pfaller, M. y cols. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314-319.
21. Espinel-Ingroff, A., Bartlett, M., Bowden, R. y cols. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. Antimicrob Agents Chemother 1997; 35: 139-143.
22. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed Standard NCCLS document M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa 1998.
23. Odds, F.C., Gerven, F.V., Espinel-Ingroff, A. y cols. Evaluation of possible correlation between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42: 282-288.
24. Gehrt, A., Peter, J., Pizzo, P.A., Walsh, T.J. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MIC of antifungal agents by broth microdilution method. J Clin Microbiol 1995; 33: 1302-1307.
25. Pujol, L., Guarro, J., Sala, J., Riba, M.D. Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for amphotericin B against Fusarium. Antimicrob Agents Chemother 1997; 41: 808-811.
26. Llop, C., Pujol, I., Aguilar, C., Sala, J., Riba, D., Guarro, J. Comparison of three methods of determining MIC for filamentous fungi using different end point criteria and incubation periods. Antimicrob Agents Chemother 2000; 44: 239-242.
27. Pujol, I., Fernández-Ballart, J., Guarro, J. Effect of inoculum from on in vitro antifungal susceptibilities of Aspergillus spp. Antimicrob Agents Chemother 2001; 47: 715-718.
28. Rambali, B., Fernández, J.A., Nuffel, L.V. y cols. Susceptibility testing of pathogenic fungi with itraconazole: A process analysis of test variables. J Antimicrob Chemother 2001; 48: 163-177.
29. Papithou, N.I., Ostrosky-Zeichner, L., Paetznick, V.L., Rodríguez, J.R., Chen, E., Rex, J.H. In vitro activities of investigational triazoles against Fusarium species: Effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002; 46: 3298-3300.
30. Espinel-Ingroff, A., Bartlett, M., Chaturvedi, V. y cols. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp. NCCLS collaborative evaluation. Antimicrob Agents Chemother 2001; 45: 1828-1835.
31. Espinel-Ingroff, A., Fothergill, A., Peter, J., Rinaldi, M.G., Walsh, T.J. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp. NCCLS collaborative study. J Clin Microbiol 2002; 40: 3204-3208.
32. Espinel-Ingroff, A., Chaturvedi, V., Fothergill, J., Rinaldi, M.G. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol. 2002; 40: 3776-3781.
33. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard NCCLS document M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa 2002.
34. National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts. Proposed Guideline NCCLS document M44-P. National Committee for Clinical Laboratory Standards, Wayne, Pa 2003.
35. Barry, A.L., Brown, S.D. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol 1996; 34: 2154-2157.
36. May, J.L., King, A., Warren, C.A. Fluconazole disk diffusion testing for the routine laboratory. J Antimicrob Chemother 1997; 40: 511-516.
37. Meis, J., Petrou, M., Bille, J., Ellis, D., Gibbs, D., and the Global Antifungal Surveillance Group. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn Microbiol Infect Dis 2000; 36: 215-223.
38. Rubio, M.C., Gil, J., Ramírez de Ocáriz, I., Benito, R., Rezusta, A. Comparison of results obtained by testing with three different agar media and by the NCCLS M27-A method for in vitro testing of fluconazole against Candida spp. J Clin Microbiol 2003; 41: 2665-2668.
39. Pfaller, M.A., Diekema, D.J., Messer, S.A., Boyken, L., Hollis, R.J. Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and E-test methods: Report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003; 41: 1440-1446.
40. Espinel-Ingroff, A., Pfaller, M., Messer, S.A. y cols. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J Clin Microbiol 1999; 37: 591-595.
41. Yamaguchi, H., Uchida, K., Nagino, K., Matsunaga, T. Usefulness of a colorimetric method for testing antifungal drug susceptibilities of Aspergillus species to voriconazole. J Infect Chemother 2002; 8: 374-377.
42. Martín-Mazuelos, E., Pemán, J., Valverde, A., Chaves, M., Serrano, M.C., Cantón, E. Comparison of the Sensititre YeastOne colorimetric antifungal panel and E-test with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother 2003; 52: 365-370.
43. Arendrup, M., Lundgren, B., Jensen, I.M., Hanse, B.S., Frimodt-Møller, N. Comparison of E-test and tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. J Antimicrob Chemother 2001; 47: 521-526.
44. Chryssanthou, E., Cuenca-Estrella, M. Comparison of the antifungal susceptibility testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841-3844.
45. Maxwell, M.J., Messer, S.A., Hollis, R.J. y cols., International Fungal Surveillance Participant Group. Evaluation of E-test method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 1087-1090.
46. Pfaller, J.B., Messer, S.A., Hollis, R.J., Diekema, D.J., Pfaller, M.A. In vitro susceptibility testing of Aspergillus spp. Comparison of E-test and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol 2003; 41: 1126-1129.
47. Pfaller, M.A., Messer, S.A., Boyken, L., Hollis, R.J., Diekema, D.J. In vitro susceptibility of filamentous fungi: Comparison of E-test and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis 2003; 45: 241-244.
48. Matar, M.J., Ostrosky-Zeichner, L., Paetznick, L., Rodríguez, J.R., Chen, E., Rex, J.H. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother 2003; 47: 1647-1651.
49. Rex, J.H., Pfaller, M.A., Galgiani, J.N. y cols., Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infectios. Clin Infect Dis 1997; 24: 235-247.
50. Lee, S.C., Fung, C.P., Huang, J.S. y cols. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000; 44: 2715-2718.
51. Law, D., Moore, C.B., Denning, D.W. Discrepancies associated with the measurement of itraconazole serum concentrations by bioassays. J Antimicrob Chemother 1999; 44: 577-578.
52. Denning, D.W., Radford, S.A., Oakley, K.L., Hall, L., Johnson, E.M., Warnock, D.W. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401-414.
53. Denning, D.W., Venkateswarlu, K., Oakley, K.L. y cols. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364-1368.
54. Denning, D.W. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
55. Cuenca-Estrella, M., Rodríguez-Tudela, J.L. ¿Pueden basarse las indicaciones de los antifúngicos en los estudios de sensibilidad? Rev Iberoam Micol 2002; 19: 133-138.
56. Odds, F.C. Personal opinion: Can antifungal sensitivity tests predict clinical treatment outcomes? Rev Iberoam Micol 1997; 14: 83-84.
57. Rex, J.H., Pfaller, M.A. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35: 982-989.
58. Craig, W.A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
59. Mouton, J.W., van Ogtrop, M.L., Andes, D., Craig, W.A. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agenst Chemother 1999; 43: 2473-2478.
60. Rex, J.H., Pfaller, M.A., Walsh, T.J. y cols. Antifungal susceptibility testing: Practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-658.
61. Louie, A., Drusano, G.L., Banerjee, P. y cols. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42: 1105-1109.
62. Andes, D., van Ogtrop, M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999; 43: 2116-2120.
63. Burgess, D.S., Hastings, R.W. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology. Diagn Microbiol Infect Dis 2000; 38: 87-93.
64. Patterson, T.F. Fungal susceptibility testing: Where are we now? Transpl Infect Dis 2002; 4 (Suppl. 3): 38-45.
65. Andes, D., Marchillo, K., Stamstad, T., Conklin, R. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1193-1199.
66. Andes, D., Marchillo, K., Stamstad, T., Conklin, R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-3169.
67. Andes, D., Marchillo, K., Coklin R. y cols. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48: 137-142.